Participant flow

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma · Source last updated 2017-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.

   id

   FG000

   title

   Treatment (Single-agent Depsipeptide)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   2. reasons

      1. group Id

         FG000

         num Subjects

         30

      type

      Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Second Primary

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Toxicity

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Never started treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         39

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice